Showing 1 to 12 of 30 results
Pfizer Acquires Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer, the US pharmaceutical giant, has acquired the biopharmaceutical company Metsera for $4.9 billion to enter the obesity drug market, gaining access to Metsera's pipeline of obesity and cardiometabolic therapies.
Pfizer Acquires Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer, the US pharmaceutical giant, has acquired the biopharmaceutical company Metsera for $4.9 billion to enter the obesity drug market, gaining access to Metsera's pipeline of obesity and cardiometabolic therapies.
Progress
40% Bias Score
Pfizer to Acquire Metsera for $7.3 Billion
Pfizer is close to acquiring the weight-loss drug startup Metsera for $7.3 billion, marking Pfizer's first major acquisition in two years and a significant entry into the lucrative weight-loss drug market.
Pfizer to Acquire Metsera for $7.3 Billion
Pfizer is close to acquiring the weight-loss drug startup Metsera for $7.3 billion, marking Pfizer's first major acquisition in two years and a significant entry into the lucrative weight-loss drug market.
Progress
32% Bias Score
FDA May Not Renew Pfizer's Covid-19 Vaccine for Young Children, Creating Potential Shortage
The US Food and Drug Administration (FDA) may not renew Pfizer's Covid-19 vaccine for children under five this fall, creating a potential vaccine shortage as Moderna's vaccine is only approved for children with pre-existing health conditions; this impacts the already low vaccination rates among this...
FDA May Not Renew Pfizer's Covid-19 Vaccine for Young Children, Creating Potential Shortage
The US Food and Drug Administration (FDA) may not renew Pfizer's Covid-19 vaccine for children under five this fall, creating a potential vaccine shortage as Moderna's vaccine is only approved for children with pre-existing health conditions; this impacts the already low vaccination rates among this...
Progress
40% Bias Score
Pfizer's Q2 Earnings: 53% Chance of Positive One-Day Return Despite Lower Projections
Pfizer's upcoming earnings announcement on August 5th, 2025, is anticipated to reveal an EPS of $0.58 and sales of $13.53 billion, down from the prior year's $0.60 EPS and $13.28 billion in sales; however, historical data shows a 53% likelihood of a positive one-day stock return following earnings a...
Pfizer's Q2 Earnings: 53% Chance of Positive One-Day Return Despite Lower Projections
Pfizer's upcoming earnings announcement on August 5th, 2025, is anticipated to reveal an EPS of $0.58 and sales of $13.53 billion, down from the prior year's $0.60 EPS and $13.28 billion in sales; however, historical data shows a 53% likelihood of a positive one-day stock return following earnings a...
Progress
40% Bias Score
EU Parliament Debates No-Confidence Motion Against Von der Leyen; Netherlands and Poland Sign Defense Agreement
The European Parliament debates a no-confidence motion against President von der Leyen for refusing to release text messages with Pfizer's CEO; Dutch PM Schoof and Minister Brekelmans visit Poland to sign a defense agreement; and Israel conducts airstrikes in Yemen targeting Houthi sites.
EU Parliament Debates No-Confidence Motion Against Von der Leyen; Netherlands and Poland Sign Defense Agreement
The European Parliament debates a no-confidence motion against President von der Leyen for refusing to release text messages with Pfizer's CEO; Dutch PM Schoof and Minister Brekelmans visit Poland to sign a defense agreement; and Israel conducts airstrikes in Yemen targeting Houthi sites.
Progress
40% Bias Score
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
Progress
40% Bias Score
Pfizer to Acquire Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer announced a $4.9 billion cash acquisition of Metsera, a biopharmaceutical firm with a pipeline of obesity and cardiometabolic disease treatments, to expand into the growing obesity drug market.
Pfizer to Acquire Metsera for $4.9 Billion to Enter Obesity Drug Market
Pfizer announced a $4.9 billion cash acquisition of Metsera, a biopharmaceutical firm with a pipeline of obesity and cardiometabolic disease treatments, to expand into the growing obesity drug market.
Progress
44% Bias Score
Pfizer Publishes Covid-19 Vaccine Data Following Trump's Call for Transparency
Responding to President Trump's request, Pfizer released over 200 news releases, 27 peer-reviewed publications, and pledged more data on its Covid-19 vaccine's impact, highlighting its role in saving millions of lives and boosting the economy.
Pfizer Publishes Covid-19 Vaccine Data Following Trump's Call for Transparency
Responding to President Trump's request, Pfizer released over 200 news releases, 27 peer-reviewed publications, and pledged more data on its Covid-19 vaccine's impact, highlighting its role in saving millions of lives and boosting the economy.
Progress
36% Bias Score
US Cuts $500 Million in mRNA Vaccine Research Funding
The US Department of Health and Human Services, led by Robert F. Kennedy Jr., slashed $500 million in mRNA vaccine research funding, citing ineffective protection against respiratory infections, despite expert consensus on the technology's life-saving role during the COVID-19 pandemic and its potent...
US Cuts $500 Million in mRNA Vaccine Research Funding
The US Department of Health and Human Services, led by Robert F. Kennedy Jr., slashed $500 million in mRNA vaccine research funding, citing ineffective protection against respiratory infections, despite expert consensus on the technology's life-saving role during the COVID-19 pandemic and its potent...
Progress
48% Bias Score
Bicillin L-A Shortage Threatens Progress Against Congenital Syphilis
Pfizer warns of a Bicillin L-A shortage, impacting syphilis treatment during pregnancy, following a July recall of contaminated lots; the sole US supplier faces challenges in meeting demands, threatening recent progress against rising congenital syphilis rates.
Bicillin L-A Shortage Threatens Progress Against Congenital Syphilis
Pfizer warns of a Bicillin L-A shortage, impacting syphilis treatment during pregnancy, following a July recall of contaminated lots; the sole US supplier faces challenges in meeting demands, threatening recent progress against rising congenital syphilis rates.
Progress
36% Bias Score
US Cuts Funding for Moderna Bird Flu Vaccine Amidst Controversy
The Trump administration cut a $766 million grant for Moderna's experimental bird flu vaccine, citing unmet scientific standards; however, Pfizer's CEO defended the vaccine's efficacy, highlighting the success of mRNA vaccines and expressing concern about declining vaccination rates.
US Cuts Funding for Moderna Bird Flu Vaccine Amidst Controversy
The Trump administration cut a $766 million grant for Moderna's experimental bird flu vaccine, citing unmet scientific standards; however, Pfizer's CEO defended the vaccine's efficacy, highlighting the success of mRNA vaccines and expressing concern about declining vaccination rates.
Progress
64% Bias Score
FDA Mandates Updated Covid-19 Vaccine Warning Labels
The FDA mandates updated Covid-19 vaccine warning labels for Pfizer-BioNTech and Moderna, specifying a slightly increased risk of myocarditis/pericarditis in males aged 16-25 based on health insurance claims data analysis showing 38 cases per million doses, highlighting the importance of transparenc...
FDA Mandates Updated Covid-19 Vaccine Warning Labels
The FDA mandates updated Covid-19 vaccine warning labels for Pfizer-BioNTech and Moderna, specifying a slightly increased risk of myocarditis/pericarditis in males aged 16-25 based on health insurance claims data analysis showing 38 cases per million doses, highlighting the importance of transparenc...
Progress
48% Bias Score
Showing 1 to 12 of 30 results